Evidence map›Paper›PMID 25640655›Full record

ArticleCellular & molecular immunology2016

Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells.

Rhonda L Taylor, Mark N Cruickshank, Mahdad Karimi, Han Leng Ng, Elizabeth Quail, Kenneth M Kaufman, John B Harley, Lawrence J Abraham, Betty P Tsao, Susan A Boackle and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Rhonda L TaylorSchool of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, WA, Australia.
Mark N CruickshankTelethon Kids Institute, The University of Western Australia, Crawley, WA, Australia.
Mahdad KarimiBiochemistry and Molecular Biology, School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA, Australia.
Han Leng NgSchool of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, WA, Australia.
Elizabeth QuailBiochemistry and Molecular Biology, School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA, Australia.
Kenneth M KaufmanCincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
John B HarleyCincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Lawrence J AbrahamSchool of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, WA, Australia.
Betty P TsaoDivision of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Susan A BoackleDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, USA.
Daniela UlgiatiSchool of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, WA, Australia.
University of Western Australia · AUCincinnati Children's Hospital Medical Center · USThe Kids Research Institute Australia · AUUnited States Department of Veterans Affairs · USUniversity of California, Los Angeles · USUniversity of Colorado Denver · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
Program Project in the Genetics of SLEP01AR049084 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2002 to 2012
$12.7M
SequencingP01AI083194 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI SIVILS, KATHY L. · 2009 to 2013
$9.6M
HLA GENE COMPLEMENTATION IN PRIMARY SJOGREN'S AND LUPUSR01AI024717 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KOTTYAN, LEAH CLAIRE, WEIRAUCH, MATTHEW TYSON · 1987 to 2025
$7.8M
Genetic Linkage in LupusR37AI024717 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI HARLEY, JOHN BARKER · 2005 to 2014
$4.2M
Better Outcomes for Children: GWAS & PheWAS in eMERGEII.U01HG006828 · NHGRI · CINCINNATI CHILDRENS HOSP MED CTR · PI HARLEY, JOHN BARKER, HOLM, INGRID ADELE · 2012 to 2014
$4.0M
Functional Analysis of Complement Receptor 2 as a Lupus Susceptibility GeneR01AI070983 · NIAID · UNIVERSITY OF COLORADO DENVER · PI BOACKLE, SUSAN A. · 2006 to 2010
$2.4M
Analysis of Lupus Susceptibility Genes for Treatment and Prevention of DiseaseK24AI078004 · NIAID · UNIVERSITY OF COLORADO DENVER · PI BOACKLE, SUSAN A. · 2010 to 2014
$739k
NCATS NIH HHS UL1 TR001417NCATS NIH HHS UL1 TR001425NHGRI NIH HHS U01 HG006828NHGRI NIH HHS U01HG006828NIAID NIH HHS K24 AI078004NIAID NIH HHS P01 AI083194NIAID NIH HHS P01AI083194NIAID NIH HHS R01 AI024717NIAID NIH HHS R01 AI070983NIAID NIH HHS R01AI070983NIAID NIH HHS R37 AI024717NIAID NIH HHS R37AI024717NIAMS NIH HHS P01 AR049084NIAMS NIH HHS P01AR049084
6 · The paper itself

Abstract

Complement receptor 2 (CR2/CD21) is predominantly expressed on the surface of mature B cells where it forms part of a coreceptor complex that functions, in part, to modulate B-cell receptor signal strength. CR2/CD21 expression is tightly regulated throughout B-cell development such that CR2/CD21 cannot be detected on pre-B or terminally differentiated plasma cells. CR2/CD21 expression is upregulated at B-cell maturation and can be induced by IL-4 and CD40 signaling pathways. We have previously characterized elements in the proximal promoter and first intron of CR2/CD21 that are involved in regulating basal and tissue-specific expression. We now extend these analyses to the CR2/CD21 core promoter. We show that in mature B cells, CR2/CD21 transcription proceeds from a focused TSS regulated by a non-consensus TATA box, an initiator element and a downstream promoter element. Furthermore, occupancy of the general transcriptional machinery in pre-B versus mature B-cell lines correlate with CR2/CD21 expression level and indicate that promoter accessibility must switch from inactive to active during the transitional B-cell window.

Indexed as

Promoter Regions, GeneticTranscription Initiation SiteBase SequenceCD40 AntigensCell DifferentiationCell Line, TumorExonsGene Expression RegulationHumansInterleukin-4IntronsK562 CellsMolecular Sequence DataPrecursor Cells, B-LymphoidReceptors, Complement 3dSignal TransductionCD40 AntigensIL4 protein, humanInterleukin-4Receptors, Complement 3d

Identifiers

PMID25640655
PMCPMC4711682
OpenAlexW2014247735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.